Somewhat Positive News Coverage Somewhat Unlikely to Affect National Health Investors (NHI) Stock Price

News articles about National Health Investors (NYSE:NHI) have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. National Health Investors earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the real estate investment trust an impact score of 45.2967056273915 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.

NHI stock opened at $66.31 on Tuesday. National Health Investors has a fifty-two week low of $62.71 and a fifty-two week high of $81.60. The company has a market capitalization of $2,741.12, a P/E ratio of 17.13, a price-to-earnings-growth ratio of 3.40 and a beta of 0.48. The company has a current ratio of 13.85, a quick ratio of 13.85 and a debt-to-equity ratio of 0.87.

How to Become a New Pot Stock Millionaire

National Health Investors (NYSE:NHI) last announced its earnings results on Friday, February 16th. The real estate investment trust reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $1.33 by ($0.43). National Health Investors had a net margin of 57.19% and a return on equity of 12.20%. The firm had revenue of $71.06 million for the quarter, compared to analyst estimates of $71.36 million. equities research analysts expect that National Health Investors will post 5.5 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, May 10th. Shareholders of record on Friday, March 30th will be issued a dividend of $1.00 per share. The ex-dividend date is Wednesday, March 28th. This represents a $4.00 dividend on an annualized basis and a dividend yield of 6.03%. This is a boost from National Health Investors’s previous quarterly dividend of $0.95. National Health Investors’s dividend payout ratio is presently 98.19%.

A number of equities analysts recently weighed in on NHI shares. Stephens set a $79.00 price target on National Health Investors and gave the stock a “buy” rating in a report on Friday, January 12th. Stifel Nicolaus set a $76.00 price target on National Health Investors and gave the stock a “buy” rating in a report on Saturday, February 17th. Hilliard Lyons raised National Health Investors from a “neutral” rating to a “buy” rating in a report on Friday, February 16th. Mizuho reaffirmed a “hold” rating and issued a $70.00 price target on shares of National Health Investors in a report on Monday, February 26th. Finally, SunTrust Banks set a $70.00 price target on National Health Investors and gave the stock a “hold” rating in a report on Saturday, February 17th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $77.75.

In other news, CEO D. Eric Mendelsohn bought 2,000 shares of National Health Investors stock in a transaction on Thursday, February 22nd. The stock was acquired at an average price of $65.47 per share, with a total value of $130,940.00. Following the completion of the acquisition, the chief executive officer now directly owns 10,580 shares of the company’s stock, valued at $692,672.60. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP John L. Spaid bought 500 shares of National Health Investors stock in a transaction on Thursday, February 22nd. The shares were purchased at an average cost of $64.95 per share, with a total value of $32,475.00. Following the acquisition, the vice president now directly owns 971 shares of the company’s stock, valued at $63,066.45. The disclosure for this purchase can be found here. Insiders have acquired 2,812 shares of company stock valued at $183,910 in the last three months. Insiders own 5.19% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Ticker Report and is owned by of Ticker Report. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3303529/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-national-health-investors-nhi-stock-price.html.

National Health Investors Company Profile

National Health Investors, Inc is a self-managed real estate investment trust (REIT) specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. The Company is engaged in the business of owning and financing healthcare properties.

Insider Buying and Selling by Quarter for National Health Investors (NYSE:NHI)

Receive News & Ratings for National Health Investors Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Health Investors and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Citi Trends, Inc.  Shares Sold by TIAA CREF Investment Management LLC
Citi Trends, Inc. Shares Sold by TIAA CREF Investment Management LLC
International Speedway Co.  Position Cut by TIAA CREF Investment Management LLC
International Speedway Co. Position Cut by TIAA CREF Investment Management LLC
Tiemann Investment Advisors LLC Has $2.11 Million Holdings in Oracle Co.
Tiemann Investment Advisors LLC Has $2.11 Million Holdings in Oracle Co.
Bodycote  Downgraded by Zacks Investment Research to “Sell”
Bodycote Downgraded by Zacks Investment Research to “Sell”
Aviva  Downgraded by Zacks Investment Research to “Hold”
Aviva Downgraded by Zacks Investment Research to “Hold”
Zacks Investment Research Lowers Aaron’s  to Sell
Zacks Investment Research Lowers Aaron’s to Sell


© 2006-2018 Ticker Report. Google+.